Studies using rodent and adult human prostate stem-progenitor cell models indicate that exposure to bisphenol A (BPA) during development increases susceptibility of the prostate gland to premalignancy later in life. A novel human organoid model has now been generated to study the effects of BPA on embryonic human prostate development.
Bisphenol A (BPA), an environmental oes trogen, has been used for commercial plastic production since the 1950s. Biomonitoring studies indicate that BPA exposure is wide spread and continuous in humans.
1 BPA is detectable in pregnant and nonpregnant women, and also in newborns, 2 suggesting that exposure to BPA might start at con ception. In rats, exposure to low, environ mentally relevant doses of BPA during development increases the susceptibility of the prostate gland to premalignancy later in life.
3 Although high urinary levels of BPA have been associated with prostate cancer in humans, 4 clinical evidence for the adverse effects of early life exposure to BPA on prostate health is still lacking. In a new study, CalderonGierszal and Prins 5 have addressed this important issue using an in vitro model of de novo generation of prostate organoids through the directed dif ferentiation of human embryonic stem cells (hESCs). They used this pioneering model to evaluate the effect of lowdose BPA on the development and maturation of prostate organoids starting from the hESC stage.
An important feature of this model is that human prostate organoids were gen erated entirely from embryonic stem cells, which are pluripotent and have a poten tial to differentiate into any of the three embryonic germ cell layers-endoderm, mesoderm and ectoderm. Prins et al.
6 pre viously studied the direct effects of BPA on epithelial stemlike cells cultured from the prostates of young adult men. In contrast to hESCs, adult prostate stemlike cells are multipotent and able to differentiate into multiple lineages of epithelial cellsluminal, basal and transit amplifying cells. The use of hESCs in the latest study widens the study window for investigating the effects of BPA to include the very early embryonic stages.
The study by CalderonGierszal and Prins 5 provides for the first time a robust method by which human prostate organ oids of entirely human origin can be gener ated. Directed differentiation of hESCs was induced by temporal exposure to defined growth factors and steroids known to be required in normal prostate development. The resulting hESCderived prostate organ oids were composed of epithelium and stroma purely of human origin. In previ ously established human prostate models, [7] [8] [9] rodent mesenchyme was required for pros tate induction, meaning that the resulting organoids were 'hybrid combinants' com posed of human epithelium and rodent stroma. The progression into the use of pure human prostate organoids remark ably enhances the human relevance of this model for investigating endocrine d isruption by BPA.
Although the de novo generation of threedimensional prostate organoids was carried out entirely in vitro, hESCs were induced by growth factors and steroids to differentiate into specific developmental stages.
5 Firstly, differentiation of hESCs into definitive endoderm was achieved using activin. Next, endodermdifferentiated cells were driven into prostatic fate deter mination using WNT10b and fibroblast growth factor 10. Final prostate organoid maturation was achieved using a cocktail of Rspondin1, noggin, proepidermal growth factor, retinoic acid and testoster one. This model recapitulates key stages of prostate development including epithelial budding and branching morphogenesis; it also models the cytodifferentiation and functional differentiation of epithelial and stromal cells into prostaticlike structures that are similar to adult human prostate. The in vitro induction of prostate organoids provides a robust model with a welldefined morphogenic environment that enables investigation of the effects of BPA or other endocrinedisrupting chemicals.
BPA has been shown to have endocrine disrupting effects at low, environmentally relevant doses in rodent prostates 3 and human adult prostate stemprogenitor cells. 6 Whether BPA affects hESCs in normal prostate development in humans has been unknown. In the present study, low levels of BPA exposure (1 nM and 10 nM), when maintained throughout prostate induction, affected early budding morpho genesis and disrupted stem cell homeo stasis. 
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stimulating and 10 nM BPA repressing for mation of epithelial buds. The stemlike cell population was increased by 10 nM BPA, as shown by the appearance of focal stem cell nests in mature organoids. This study provides evidence that BPA targets not only adult prostate stemprogenitor cells but also hESCs. Investigations using a broader range of BPA doses are needed to validate the nonmonotonic dose-response in the current human prostate organoid setting.
The present study establishes a robust model of de novo generation of pure human prostate organoids from hESCs without rodent mesenchymal induction. Lowdose BPA exposure targets hESCs and results in the perturbation of early prostate morpho genesis and stem cell homeostasis in mature organoids. These findings suggest that early embryonic stages might be susceptible to disruption by BPA exposure in the womb.
This model could be used to delineate the effects of BPA on the early embryonic stages that occur prior to formation of the urogenital sinus (prostate precursor), and to test whether a critical window of suscep tibility to BPA exists early in fetal develop ment. Given that human fetal prostates express oestrogen receptors 10 and that developmental exposure to BPA induces epigenetic changes in rodent prostates, 3 the current in vitro model could facili tate mechanistic studies of BPAmediated oestrogen receptordependent and oestrogen receptorindependent signalling pathways and epigenetic reprogramming in a human setting. The current model could also be used to detect developmen tal d isruptors-including dietary, environ mental and pathogenic agents-that might affect disease outcomes in the prostate.
